Imaging Agent 124I-Evuzumitide for Detecting Amyloid Deposits in Systemic Amyloidosis
Tests an imaging agent to detect amyloid deposits in the heart and other organs.
Key facts
- Who runs it
- Oregon Health and Science University
- Where
- Portland, United StatesSee the site
- Trial code
- Registry title
- Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 150 people, planned
- Started
- 10 Jan 2023
- Expected to end
- 10 Mar 2028
- Type of study
- Interventional
- Treatments tested
- 124I-Evuzamitide
- Record updated
- 13 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with systemic amyloidosis, a known transthyretin gene mutation, multiple myeloma or monoclonal gammopathy of undetermined significance. They will have PET imaging with 124I-evuzumitide.
- Age
- 40 to 90 years
- Sex
- All sexes can join.
- Disease stage
- Systemic amyloidosis with known organ involvement, or carrier of a known pathogenic transthyretin gene mutation, or multiple myeloma, or monoclonal gammopathy of undetermined significance.
- Earlier treatment
- Cannot have received heparin or heparin analogs (such as enoxaparin, dalteparin, fondaparinux) within 7 days before the study drug.
- Biomarker or test result
- A known pathogenic mutation in the transthyretin gene counts for carriers; otherwise none is asked for.
Main reasons for not taking part
- Severe claustrophobia or a medical condition that prevents finishing the imaging
- Known allergy to potassium iodide treatment or to gadolinium
- Heparin or heparin analogs within 7 days before 124I-Evuzumitide
- Dialysis or eGFR <30 cc/min/1.73 m2 (cannot have gadolinium-enhanced cardiac MRI)
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Subjects will at least have one of the following conditions: systemic amyloidosis with known organ involvement, carrier of a known pathogenic mutation in the transthyretin gene, multiple myeloma, and monoclonal gammopathy of undetermined significance
- Patient willing to consent for the study and undergo the study procedures
Who cannot take part
- Has received heparin or heparin analogs (e.g., enoxaparin, dalteparin, fondaparinux) within 7 days prior to 124I-Evuzumitide administration
- Has severe claustrophobia or any medical condition that would prevent completion of the imaging protocol
- Has a known allergy to potassium iodide treatment or to gadolinium
- Patients on dialysis or those with eGFR <30 cc/min/1.73 m2 will be excluded from undergoing gadolinium-enhanced cardiac MRI
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 90 years old?
Where in United States
- Oregon Health Science UniversityPortland, United StatesContact: Ahmad Masri, MDTaking people
About the trial
What the trial wants to find out
This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1) Establish the diagnostic accuracy of 124I-evuzumitide in cardiac amyloidosis 2) Evaluate extracardiac uptake 3) identify and characterize the distribution and uptake of 124I-evuzumitide in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and 4) Correlate the uptake with the structure and function of different organs, including the heart. To achieve these goals, eligible patients will undergo primarily hybrid positron emission tomography and magnetic resonance imaging (PET/MRI). In a subgroup of patients who are unable to undergo PET/MR, computed tomography will be used instead of MRI (i.e. PET/CT). In a subgroup of patients, repeat imaging with the same modality will be done at a interval of 6-12 months. Clinically available data (demographics, phenotype, imaging, laboratory) will also be collected to characterize the disease in each patient.
The group in the trial
- Patients with ATTR-CMTreatment being tested
Patients with ATTR-CM will undergo hybrid 124I-Evuzamitide PET/MRI imaging (or PET/CT) at baseline and in a subgroup, repeat imaging will be performed at an interval of 6-12 months.
Treatment: 124I-Evuzamitide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
- Plain-language title
- Imaging Agent 124I-Evuzumitide for Detecting Amyloid Deposits in Systemic AmyloidosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05758493, who can take part
- Publications
- 124Iodine Evuzamitide Positron Emission Tomography in Patients With Established or Suspected Cardiac Amyloidosis.JACC. Cardiovascular imaging, 2026
- Record updated
- 13 April 2026